The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Predictive value of ectopic HORMAD1 tumor expression for high-dose platinum-based chemotherapy benefit in patients with high-risk HER2-negative breast cancer.
 
Leonora De Boo
No Relationships to Disclose
 
Jelmar Quist
No Relationships to Disclose
 
Mark Opdam
No Relationships to Disclose
 
Katarzyna Jozwiak
No Relationships to Disclose
 
Patrycja Gazinska
No Relationships to Disclose
 
Dennis Peters
No Relationships to Disclose
 
Hugo M. Horlings
No Relationships to Disclose
 
Tessa Gerjanne Steenbruggen
No Relationships to Disclose
 
Lars C. Steggink
No Relationships to Disclose
 
Elisabeth De Vries
Consulting or Advisory Role - Crescendo Biologics (Inst); Daiichi Sankyo (Inst); NSABP Foundation (Inst)
Research Funding - Amgen (Inst); Bayer (Inst); Crescendo Biologics (Inst); CytomX Therapeutics (Inst); G1 Therapeutics (Inst); Genentech (Inst); Regeneron (Inst); Roche (Inst); Servier (Inst); Synthon (Inst)
(OPTIONAL) Uncompensated Relationships - ESMO (Inst); RECIST (Inst); World Health Organization (Inst)
 
Gabe S. Sonke
Consulting or Advisory Role - Biovica (Inst); Novartis (Inst); Seagen (Inst)
Research Funding - Agendia (Inst); AstraZeneca/Merck (Inst); Merck Sharp & Dohme (Inst); Novartis (Inst); Roche (Inst)
 
Jourik A. Gietema
Research Funding - Abbvie (Inst); Roche/Genentech (Inst); Siemens (Inst)
 
Andrew Tutt
Employment - Institute of Cancer Research
Leadership - Institute of Cancer Research
Stock and Other Ownership Interests - InBiomotion
Honoraria - Medscape; Prime Oncology
Consulting or Advisory Role - Artios; AstraZeneca; EM Partners; GE Healthcare (Inst); Gilead Sciences; Gilead Sciences (Inst); MD Anderson Cancer Center; Merck Serono (Inst); Pfizer; Prime Oncology; VJOncology (Inst)
Research Funding - Artios (Inst); AstraZeneca (Inst); Merck KGaA (Inst); Roche/Genentech (Inst)
Patents, Royalties, Other Intellectual Property - I have i the past and may in the future be in Receipt of payments under my employer (ICR London) Rewards to inventors Scheme associated with patents held by ICR associated with the use of PARP inhibitors in BRCA 1/2 deficient cancers
Travel, Accommodations, Expenses - AstraZeneca; Pfizer
Other Relationship - Breast Cancer Now Charity (Inst); Cancer Research UK (Inst)
(OPTIONAL) Uncompensated Relationships - St Gallen Early Breast Cancer Consensus Conference
 
Marleen Kok
Consulting or Advisory Role - AstraZeneca/Daiichi Sankyo (Inst); Bristol-Myers Squibb/Medarex (Inst); MSD (Inst); Roche (Inst)
Research Funding - AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Roche (Inst)
 
Anita Grigoriadis
No Relationships to Disclose
 
Sabine C. Linn
Consulting or Advisory Role - Daiichi Sankyo (Inst)
Research Funding - Agendia (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Eurocept Pharmaceuticals (Inst); Genentech/Roche (Inst); Immunomedics (Inst); Merck (Inst); Novartis (Inst); Tesaro (Inst)
Travel, Accommodations, Expenses - Daiichi Sankyo Europe GmbH (Inst)